Publication: Lactiplantibacillus plantarum DSM20174 attenuates the progression of non-alcoholic fatty liver disease by modulating gut microbiota, improving metabolic risk factors, and attenuating adipose inflammation
| dc.contributor.author | Riezu Boj, José I. | |
| dc.contributor.author | Barajas Vélez, Miguel Ángel | |
| dc.contributor.author | Pérez Sánchez, Tania | |
| dc.contributor.author | Pajares Villandiego, María Josefa | |
| dc.contributor.author | Araña Ciordia, Miriam | |
| dc.contributor.author | Milagro Yoldi, F. I. | |
| dc.contributor.author | Urtasun Alonso, Raquel | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.date.accessioned | 2023-04-04T07:16:45Z | |
| dc.date.available | 2023-04-04T07:16:45Z | |
| dc.date.issued | 2022 | |
| dc.date.updated | 2023-04-04T07:06:42Z | |
| dc.description.abstract | Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, reaching epidemic proportions worldwide. Targeting the gut–adipose tissue–liver axis by modulating the gut microbiota can be a promising therapeutic approach in NAFLD. Lactiplantibacillus plantarum, a potent lactic-acid-producing bacterium, has been shown to attenuate NAFLD. However, to our knowledge, the possible effect of the Lactiplantibacillus plantarum strain DSM20174 (L.p. DSM20174) on the gut–adipose tissue axis, diminishing inflammatory mediators as fuel for NAFLD progression, is still unknown. Using a NAFLD mouse model fed a high-fat, high-fructose (HFHF) diet for 10 weeks, we show that L.p DSM20174 supplementation of HFHF mice prevented weight gain, improved glucose and lipid homeostasis, and reduced white adipose inflammation and NAFLD progression. Furthermore, 16S rRNA gene sequencing of the faecal microbiota suggested that treatment of HFHF-fed mice with L.p DSM20174 changed the diversity and altered specific bacterial taxa at the levels of family, genus, and species in the gut microbiota. In conclusion, the beneficial effects of L.p DSM20174 in preventing fatty liver progression may be related to modulations in the composition and potential function of gut microbiota associated with lower metabolic risk factors and a reduced M1-like/M2-like ratio of macrophages and proinflammatory cytokine expression in white adipose tissue and liver. | en |
| dc.description.sponsorship | This research was funded by Department of University, Innovation, and Digital Transformation Government of Navarra, grant number Microliver-PC131-132. | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Riezu-Boj, J. I., Barajas, M., Pérez-Sánchez, T., Pajares, M. J., Araña, M., Milagro, F. I., & Urtasun, R. (2022). Lactiplantibacillus plantarum dsm20174 attenuates the progression of non-alcoholic fatty liver disease by modulating gut microbiota, improving metabolic risk factors, and attenuating adipose inflammation. Nutrients, 14(24), 5212. https://doi.org/10.3390/nu14245212 | en |
| dc.identifier.doi | 10.3390/nu14245212 | |
| dc.identifier.issn | 2072-6643 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/45034 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | Nutrients, 2022, 14(24), 1-15 | en |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra// | en |
| dc.relation.publisherversion | https://doi.org/10.3390/nu14245212 | |
| dc.rights | © 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
| dc.rights.accessRights | Acceso abierto / Sarbide irekia | es |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Fat tissue inflammation | en |
| dc.subject | Fatty liver progression | en |
| dc.subject | Intestinal microbiota | en |
| dc.subject | Probiotics | en |
| dc.title | Lactiplantibacillus plantarum DSM20174 attenuates the progression of non-alcoholic fatty liver disease by modulating gut microbiota, improving metabolic risk factors, and attenuating adipose inflammation | en |
| dc.type | Artículo / Artikulua | es |
| dc.type | info:eu-repo/semantics/article | en |
| dc.type.version | Versión publicada / Argitaratu den bertsioa | es |
| dc.type.version | info:eu-repo/semantics/publishedVersion | en |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 2e998efa-ca5a-491e-9e7f-a8fbbd0094ce | |
| relation.isAuthorOfPublication | b6caf2f4-8c1c-4f4d-a46d-1dade8465981 | |
| relation.isAuthorOfPublication | 601df8fd-4b6f-47c4-be5d-4b81d2c1cf64 | |
| relation.isAuthorOfPublication | 57a9f97c-8c1d-48aa-99d3-8bd229eaad87 | |
| relation.isAuthorOfPublication | fc55179f-8b60-40ec-9057-a22de0f05e35 | |
| relation.isAuthorOfPublication | 64ffa81f-666a-4086-80fb-a1f290644a67 | |
| relation.isAuthorOfPublication.latestForDiscovery | 2e998efa-ca5a-491e-9e7f-a8fbbd0094ce |